Market Overview

The Portugal pharmaceutical market size reached USD 4,559.20 Million in 2024 and is projected to reach USD 7,794.72 Million by 2033, growing at a CAGR of 6.14% during 2025-2033. The market growth is driven by digital health integration initiatives that enhance healthcare delivery and patient outcomes, combined with aggressive adoption of generic medicines and biosimilars that optimize costs and increase accessibility. Investments in manufacturing innovation and international expansion strategies are further contributing to improved production efficiency and global competitiveness.

Study Assumption Years

  • Base Year: 2024
  • Historical Year/Period: 2019-2024
  • Forecast Year/Period: 2025-2033

Portugal Pharmaceutical Market Key Takeaways

  • The Portugal pharmaceutical market size reached USD 4,559.20 Million in 2024.
  • The market is expected to grow at a CAGR of 6.14% during the forecast period 2025-2033.
  • The market forecast value for 2033 is USD 7,794.72 Million.
  • Digital health integration initiatives, recognized by WHO, are significantly contributing to healthcare modernization and improved patient outcomes.
  • Aggressive policies promoting generic medicines and biosimilars have expanded market share and generated substantial healthcare cost savings.
  • Manufacturing innovation investments include advanced production technologies and growth in contract development and manufacturing organizations (CDMO) services.
  • International expansion strategies include strategic partnerships and capacity expansions, positioning local companies as competitive global players.

Sample Request Link: https://www.imarcgroup.com/portugal-pharmaceutical-market/requestsample

Market Growth Factors

The digitization level of the Portuguese healthcare system, through government plans such as the Portuguese eHealth strategy recognized by the World Health Organization, ENESIS 2020 and ENESIS 2022, as well as the reform of the Portuguese National Health Service into 39 Local Health Units in 2024, fosters the growth of the Portuguese Pharma market․ The digital health market is predicted to reach USD 543․70 million at a CAGR of 6․94% by 2029․ Digital health initiatives include electronic health records, national and cross-border health surveillance systems, and measures to strengthen operational efficiency and patient outcomes․

A driving force is the national policy for free generic and biosimilar products․ Price and market access are determined through controlled pricing and public procurement․ For instance, the cost of the first biosimilar product cannot exceed 80% of the reference biological product, and the price of other biosimilars must be at 70%․ These controls have resulted in large increases in the market shares and affordability of generics․ Local pharmaceutical firms are expanding their generic product lines in response to patent expirations to serve both domestic and export markets․

Increased investment in process innovation and internationalization, as well as the adoption of novel manufacturing technologies (e․g․ continuous tableting and spray drying), complemented by higher investment in R&D in areas such as cell therapy and anti-infective drugs by Portuguese companies are also supporting this growth․ Projections for total production are estimated to grow from EUR 343 million in 2023 to EUR 411 million in 2028 (CAGR 2․9%)․ Collaborative partnerships and increased capacity increase global regulatory and market access․ The Contract Development & Manufacturing Organization (CDMO) services sector is growing as an element of the market․

Market Segmentation

Type Insights:

  • Pharmaceutical Drugs: The market includes cardiovascular, dermatology, gastrointestinal, genito-urinary, hematology, anti-infective, metabolic disorder, musculoskeletal disorder, central nervous system, oncology, ophthalmology, and respiratory diseases drugs, reflecting a broad therapeutic coverage.
  • Biologics: Includes monoclonal antibodies (MAbS), therapeutic proteins, and vaccines, underlining the growth in advanced biologic treatments.

Nature Insights:

  • Organic: The market is segmented by organic pharmaceutical products, representing medicines derived through natural or bio-based processes.
  • Conventional: Encompasses traditional chemically synthesized pharmaceuticals.

Request Customization:

https://www.imarcgroup.com/request?type=report&id=42691&flag=E 

Regional Insights

The report segments the Portugal pharmaceutical market into Norte, Centro, A. M. Lisboa, Alentejo, and others, covering all major regional markets. Although dominant region data with specific shares or CAGR is not detailed, the segmentation provides comprehensive regional coverage for market assessment and strategic planning.

Recent Developments & News

In December 2024, Bluepharma expanded its São Martinho do Bispo factory with a new Industrial Unit for potent medicines inaugurated in 2023. This expansion supports Bluepharma’s growing presence in the US market through licensing an increasing number of medicines and technologies, thereby reinforcing its international position and opening new opportunities.

Key Players

  • Bluepharma

Customization Note:

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302